Literature DB >> 19756660

[Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with the focus on rheumatoid arthritis. Integration of a systematic literature research with the expert opinion of a large international panel of rheumatologists within the framework of the 3e initiative].

I H Tarner1, U Müller-Ladner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 19756660     DOI： 10.1007/s00393-009-0540-5

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  1 in total

1.  Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative.

Authors:  K Visser; W Katchamart; E Loza; J A Martinez-Lopez; C Salliot; J Trudeau; C Bombardier; L Carmona; D van der Heijde; J W J Bijlsma; D T Boumpas; H Canhao; C J Edwards; V Hamuryudan; T K Kvien; B F Leeb; E M Martín-Mola; H Mielants; U Müller-Ladner; G Murphy; M Østergaard; I A Pereira; C Ramos-Remus; G Valentini; J Zochling; M Dougados
Journal:  Ann Rheum Dis       Date:  2008-11-25       Impact factor: 19.103
  1 in total
  3 in total

Review 1.  [In-label treatment of inflammatory joint diseases].

Authors:  C Kneitz; C Fiehn
Journal:  Z Rheumatol       Date:  2018-09       Impact factor: 1.372

2.  [Therapy of rheumatoid arthritis with methotrexate. Claims data analysis of treatment patterns].

Authors:  J Zeidler; H Zeidler; J-M Graf von der Schulenburg
Journal:  Z Rheumatol       Date:  2012-12       Impact factor: 1.372

3.  The effects of conventional drugs in the treatment of rheumatoid arthritis on the serum lipids.

Authors:  Mansoor Karimifar; Mohammad S Sepehrifar; Hamidreza Moussavi; Mohammad B Sepehrifar; Peyman Mottaghi; Mansour Siavash; Mozhgan Karimifar
Journal:  J Res Med Sci       Date:  2018-12-28       Impact factor: 1.852
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.